Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Financial Lp Hrt Acquires 8,266 Shares

Posted by Dante Gardener on Jul 14th, 2026

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH – Get Free Report) major shareholder Financial Lp Hrt purchased 8,266 shares of the business’s stock in a transaction dated Thursday, July 9th. The shares were purchased at an average cost of $3.38 per share, for a total transaction of $27,939.08. Following the purchase, the insider directly owned 60,540 shares of the company’s stock, valued at $204,625.20. This trade represents a 15.81% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

On Friday, July 10th, Financial Lp Hrt purchased 731 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average price of $3.11 per share, for a total transaction of $2,273.41.
On Wednesday, July 8th, Financial Lp Hrt sold 18,531 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.52, for a total value of $65,229.12.
On Tuesday, July 7th, Financial Lp Hrt sold 10,580 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.33, for a total value of $35,231.40.
On Monday, July 6th, Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.51, for a total value of $31,667.22.
On Thursday, July 2nd, Financial Lp Hrt bought 7,851 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average price of $3.54 per share, for a total transaction of $27,792.54.
On Wednesday, July 1st, Financial Lp Hrt bought 3,959 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average price of $3.30 per share, for a total transaction of $13,064.70.
On Tuesday, June 30th, Financial Lp Hrt bought 6,755 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average cost of $3.23 per share, for a total transaction of $21,818.65.
On Monday, June 29th, Financial Lp Hrt bought 25,836 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average cost of $3.44 per share, for a total transaction of $88,875.84.

Shuttle Pharmaceuticals Price Performance

Shares of NASDAQ:SHPH opened at $2.96 on Tuesday. Shuttle Pharmaceuticals Holdings, Inc. has a one year low of $2.71 and a one year high of $55.90. The company has a 50 day moving average of $4.86 and a 200-day moving average of $9.96. The stock has a market cap of $1.89 million, a price-to-earnings ratio of -0.06 and a beta of 0.29.

Analyst Upgrades and Downgrades

A number of research firms have commented on SHPH. Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a research note on Saturday, July 4th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Shuttle Pharmaceuticals currently has an average rating of “Sell”.

Get Our Latest Stock Report on Shuttle Pharmaceuticals

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC acquired a new stake in shares of Shuttle Pharmaceuticals during the fourth quarter worth $26,000. Boothbay Fund Management LLC bought a new stake in Shuttle Pharmaceuticals in the 4th quarter valued at $37,000. Ikarian Capital LLC acquired a new position in Shuttle Pharmaceuticals in the 4th quarter worth $124,000. Finally, Connective Capital Management LLC acquired a new position in Shuttle Pharmaceuticals in the 3rd quarter worth $357,000. Institutional investors and hedge funds own 4.58% of the company’s stock.

About Shuttle Pharmaceuticals

(Get Free Report)

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .